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Much progress has been made over the past decade elucidating the molecular basis for a variety of muscular dystrophies (MDs). Accordingly,
there are examples of mouse models of MD whose disease progression has been halted in large part with the use of viral vector technology. Even
so, we must acknowledge significant limitations of present vector systems that must be overcome prior to successful treatment of humans with
such approaches. This review will present a variety of viral-mediated therapeutic strategies aimed at counteracting the muscle-wasting symptoms
associated with muscular dystrophy. We include viral vector systems used for muscle gene transfer, with a particular emphasis on adeno-associated
virus. Findings of several encouraging studies focusing on repair of the mutant dystrophin gene are also included. Lastly, we present a discussion
of muscle compensatory therapeutics being considered that include pathways involved in the up-regulation of utrophin, promotion of cellular
adhesion, enhancement of muscle mass, and antagonism of the inflammatory response. Considering the complexity of the muscular dystrophies, it
appears likely that a multilayered approach tailored to a patient sub-group may be warranted in order to effectively contest the progression of this
devastating disease.
© 2006 Elsevier B.V. All rights reserved.Keywords: Dystrophin; Utrophin; Adeno-associated virus; Exon skipping; Antisense oligonucleotide1. Introduction
The muscular dystrophies (MDs) are a heterogeneous group
of inherited disorders characterized by progressive skeletal
muscle degeneration. The clinical presentation of these
disorders displays a broad spectrum of variability such as the
degree and distribution of skeletal muscle involvement, cardiac/
pulmonary involvement, age of onset, rate of progression, and
mode of inheritance [1]. The diagnosis is often performed by
examination of a muscle biopsy though in many cases genetic
testing can be employed. Histologically, muscle biopsies may
present with an increased number of myofibers with centrally
located nuclei, an abnormally large myofiber size—both of⁎ Corresponding author. Tel.: +1 206 221 5363; fax: +1 206 616 8272.
E-mail address: jsc5@u.washington.edu (J.S. Chamberlain).
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doi:10.1016/j.bbadis.2006.09.007which are characteristic of an enhanced degenerative and
regenerative response, and in advanced cases replacement of
myofibers with adipose, and connective tissue, in large part due
to the loss of regenerative potential of dystrophic muscle fibers.
A variety of therapeutic options are being developed,
particularly in small animal models, to counteract the muscle
wasting associated with MD. These include autologous
myoblast transplantation [2], stem cell transfer [3,4], pharma-
cological intervention [5–7], and gene repair/replacement
strategies [8–13]. These therapies are not without significant
hurdles. For example, cell-based approaches are hindered by a
lack of efficient methods to introduce and engraft adequate
numbers of muscle precursor cells into the bulk tissue. Gene
transfer approaches are limited by difficulties associated with
producing sufficient quantities of vector, cellular tropism of the
vectors, ectopic gene expression, the need for methods to
achieve whole-body delivery of the vector, and inherent
immunological challenges. Recently, great strides have been
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an emphasis of this review. Ultimately, a combinatorial
approach involving different therapeutic strategies may be
necessary to combat the mechanical, signaling, and immune
related mechanisms that lead to dystrophy.
The dystrophinopathies are X-linked recessive disorders
caused by dystrophin deficiency. Since the discovery of the
dystrophin gene and protein over 18 years ago [14,15], more
than 30 different forms of muscular dystrophy have been
molecularly identified [16,17]. The 427 kDa skeletal muscle
specific isoform of dystrophin is a sarcolemmal protein that
interacts with many other proteins to link the extracellular
matrix to the cytoskeleton [18–20]. Dystrophin is composed of
four major structural domains (Fig. 1) [21]. The N-terminal
domain binds to F-actin filaments in the subsarcolemal
cytoskeleton. The central rod domain includes 24 triple-helical
domains, often referred to as spectrin-like repeats, and 4
strategically placed hinges that together provide flexible,
spring-like properties that are likely critical during muscle
contraction. The cysteine-rich (CR) domain along with the
distal C-terminal (CT) domain, anchor to the plasma membrane
through the dystrophin–glycoprotein complex (DGC) (Fig. 2).Fig. 1. Structural domains of the human dystrophin protein referred to in the text (scale
dystrophinΔH2-R19Δ (227 KDa); (D)Micro-dystrophinΔR4-R23 (132 KDa). ABD
rich domain; CT: C-terminal domain; CH: calponin homology motifs; WW:WW dom
SBD: syntrophin-binding domain; DbBD: dystrobrevin-binding domain; syn: location
amino acids 3462–3483); CC: coiled coil motifs (CC1 spans amino acids 3506–35
sequence). Hinge 4 spans amino acids 3041–3112.23 Basic repeats are shown in w
Feener, CA Nature 1999.Thus, the structural components of dystrophin mediate a
mechanical function that acts to stabilize and link the muscle
cell membrane and cytoskeleton. The lack of a functional
dystrophin protein results in the loss of the DGC and causes
instability of sarcolemma. These deficiencies ultimately lead to
chronic muscle damage and degenerative pathology.
Studies of components of the DGC in non-muscle tissues
also strongly support a signaling role for some of these proteins
[22–24]. The analogy of the DGC to integrin and caveolin-3
protein complexes is compelling: like the DGC, these are
membrane proteins that, when mutated, cause muscular dystro-
phies [25–28]. In common with these multimeric complexes are
shared signal transduction cascades that mediate cell survival/
death pathways and cell defense mechanisms. The similarities
suggest common pathogenetic mechanisms leading to cell death
when the complexes and associated signaling functions are
disrupted. For example, the DGC has been documented as
interacting with signaling molecules such as calmodulin [29],
Grb2 [30], extracellular signal-related kinase (ERK) [31,32],
and neuronal nitric oxide synthase (nNOS) [33]. Membrane-
associated integrin receptors exist as alpha- and beta-subunit
heterodimers, which like the DGC mediate extracellular matrixis approximate). (A) Dystrophin (427 KDa); (B) Utrophin (395 KDa); (C) Mini-
: actin-binding domains; H: hinge regions; R: spectrin-like repeats; CR: cysteine-
ain; EF: EF-hand motifs; ZZ: ZZ domain; DgBD: dystroglycan-binding domain;
of the syntrophin contact sites (syn1 spans amino acids 3427–3461; syn2 spans
93; CC2 spans amino acids 3558–3593 as determined from the primary cDNA
hite, the others in blue. The location of the alternatively spliced exons is from
Fig. 2. Diagram of the dystrophin–glycoprotein (DGC) complex. This complex includes the integral components (dystrophin with the cysteine-rich (CR)), C-terminal
(C) and N-terminal (N) regions, the sarcolemma associated α, β-dystroglycans, the α, β, γ, and δ-sarcoglycans (Sg), α-dystrobrevin, the syntrophins, sarcospan
(Spn)), an extracellular ligand (laminin-2), intracellular binding partners (F-actin, desmin intermediate filament (DIF), and syncoilin (S)), non-associated caveolin-3
and dysferlin, and signaling molecules associated with the complex (Grb2, and nNOS). The dystroglycans and sarcoglycans are shown to be glycosylated, and
phosphorylation sites are represented on dystrophin, α-dystrobrevin 1, β-dystroglycan, the syntrophins, and α-, β- and γ-sarcoglycans.
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adhesion kinase, paxillin and Rho A are examples of proteins
involved in focal adhesion mechanotransduction. Commonality
of signaling pathways to both the DGC and integrins includes
the Ras/MAPK pathway by way of adaptor proteins such as
Grb2. As with the DGC, caveolins serve as scaffolding proteins
for signaling complexes at the membrane, and are known to
compartmentalize multiple molecules involved in a variety of
signaling pathways Caveolin is largely thought to inhibit cell
growth and proliferation by modifying the function of a variety
of molecules involved in signaling pathways such as nNOS
[34], src tyrosine kinases [35], G-proteins [36], MAP kinasecascades [37], adenylyl cyclase [38], protein kinase A [39],
protein kinase C (PKC) [40], epidermal or platelet derived
growth factor receptor [41,42], or transforming growth factor
receptor pathways [39]. Recently, caveolin-3, overexpression in
cardiac myoblasts resulted in the inhibition of growth signal as
demonstrated by calcium dependent attenuation of ERK
signaling; suggested to be acting through PKC [43].
Perturbance of these and other signaling pathways could
progressively add to the repetitive cycles of degeneration that
over time leads to advanced muscle wasting.
The core skeletal muscle DGC is composed of dystrophin,
the sarcoglycans (SGs) (α, β, γ, and δ-SG), dystroglycans
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Additionally, a number of extra- and intracellular proteins are
less tightly associated with the DGC, such as neuronal nitric
oxide synthase (nNOS) [33], dystrobrevin [44,45], caveolin-3
[46] and laminin-2 [47]. The observation that expression of
several DGC members was abnormal in a variety of different
types of MD subsequently led to the realization that the genes
for these DGC members were mutated in other forms of MD
[21,48,49]. For the purpose of this review, Duchenne muscular
dystrophy (DMD) will serve as the model for current viral-
mediated gene transfer approaches being developed in animal
models with the implicit assumption that these methods might
also be applied to other forms of MD.
DMD is the most common inherited neuromuscular disorder,
affecting 1 in 3500 newborn males worldwide [50]. DMD
results from mutations within the dystrophin gene [51,52]. This
gene is ∼2.5 MB and consists of 79 exons, including 7
promoters with 3 full-length isoforms (expressed in muscle,
brain, and cerebellar Purkinje neurons), and an additional 4
truncated isoforms (Dp260; Dp140; Dp116; and Dp71)
produced from separate promoters within the gene. The gene
is the largest identified to date, which may account for the high
frequency of mutation [53]. Close to 30% of cases arise from
spontaneous mutations [54]. Approximately 60% of mutations
causing DMD are deletions of large segments of the gene
usually including one or more exons [14,55,56], and a smaller
∼5% of mutations are duplications of large segments of the
gene [56]. Such mutations can result in mRNA instability, and/
or bring about premature termination of translation leading to an
unstable, incomplete protein that is nonfunctional and rapidly
degraded. Some mutations in the dystrophin gene can lead to
deletion of part of the coding sequence where the reading frame
is maintained; such mutations result in a semifunctional,
internally deleted dystrophin protein associated with a milder
Becker muscular dystrophy (BMD) [14]. Lastly, former studies
in transgenic mice have demonstrated not only the prevention of
abnormal mechanical properties, but also non-toxic side effects
of the dystrophin protein [57], further suggesting that DMD can
be amendable to a gene replacement strategy.
2. Model systems
The development of potential treatments has been greatly
assisted by the discovery of a natural genetic model of DMD:
the mdx mouse [58]. The mdx mouse is dystrophin deficient
owing to a point mutation that leads to a premature stop codon
and the production of an unstable peptide [59]. Transgenic mdx
mice expressing recombinant dystrophin cDNAs have revealed
a wide therapeutic window, with prevention of pathology being
achieved with dystrophin expression ranging from 0.2 times to
50 times normal endogenous levels [57,60,61]. Dystrophin
expression can be restored in mdx mice by several routes,
including drug administration, the use of anti-sense oligonu-
cleotides targeted against the mutant exon, stem cell transplan-
tation, and dystrophin gene transfer with viral or non-viral
vectors. A related mouse model that more closely mimics the
clinical picture in DMD patients is the dystrophin and utrophindouble knock out (dko) mouse [62]. A somewhat more
attractive model because of its larger size and severe phenotype
may be that of the canine x-linked muscular dystrophy (cxmd)
model [63,64].
3. Adenovirus
Gene transfer vectors derived from adenovirus (Ad) have
provided a wealth of knowledge that includes but is not limited
to various stages of the viral life cycle, viral tropism,
transduction efficiency, and the interplay between viral
infection and the host immune response. In brief, adenoviruses
are medium-sized (90–100 nm), nonenveloped icosohedral
viruses containing a double-stranded DNA genome. There are
>50 immunologically distinct serotypes (6 subgenera: A
through F) that can cause human infections, most of which
are benign and are targeted to the respiratory tract. These
subgenera are distinguished from one another based on
differential hemagglutination patterns, oncogenic potential,
and DNA G+C content [65]. Subgroup C serotypes 2 or 5
are the major types used as viral vectors. The wild type
adenovirus genome is approximately 35 kb [66,67]. There are
four early transcriptional units (E1, E2, E3 and E4), which have
regulatory functions, and a late transcript, which codes for
structural proteins. Progenitor or first generation vectors have
the E1 and often the E3 gene deleted, with the missing E1 genes
being supplied in trans from an E1 region integrated into a
producer cell such as the human fetal kidney cell line 293 [68].
Second generation vectors additionally carry deletions of the
E2b or E4 regions [69,70]. The most recent third generation or
‘helper dependent’ (hd) or gutted vectors contain only the
inverted terminal repeats (ITRs) and a packaging sequence
around the transgene with all of the necessary viral genes being
provided in trans [71,72].
Attractive properties of Ad vectors included stable growth to
very high titers (>1011 particles /ml), a large transgene carrying
capacity, very efficient transduction of target cells in vitro and in
vivo, the ability to infect post-mitotic cells such as myotubes,
the relative ease of genome manipulation and the ability to
generate high levels of transgene expression. A first-generation
adenovirus, with a limited insert capacity of∼8 kb, was the first
viral vector to successfully deliver a human miniaturized
dystrophin cDNA to mdx mice by intramuscular administration
[73]. The cDNA used in this study was deleted for segments
encoded on exons 17 to 48 producing a ∼200 kd protein that
lacks most of the central rod domain, and was previously
observed in a BMD patient [74]. In this study correct
localization of a minidystrophin protein within the injected
muscle was found in ∼50% of the myofibers and persisted for
up to 3 months. As with any viral vector there are distinct
advantages and disadvantages to its use (Table 1). Several of
these limitations have been overcome with use of the helper-
dependent or gutted adenoviral vectors (hdAd) that are deleted
for all of the viral protein coding sequences. The use of these
vectors has led to a reduced immune response, improved
transgene expression, and larger transgene carrying capacity
[75–77]. The use of hdAd to deliver dystrophin to neonatal or
Table 1
Properties of viral vector systems
Vector (1st and 2nd
gen.) Adeno
(Gutless)
Adeno
AAV Lentivirus
Genome dsDNA dsDNA ssDNA RNA
Capacity (kb) ∼8.3 a 27–29 ∼4.8 ∼7.5–9a
Size (diameter) ∼80 nm ∼80 nm ∼20 nm ∼80 nm
Integration No No No/Yes b Yes
Non-dividing
cell transduction
Yes Yes Yes Yes
Duration of
expression
Short Long Long Long
CTL induction Yes Yes No/Yes No
Pre-existing
immunity
Yes Yes No/Yes No
Safety issues Inflammation Cytotoxicity Insertional
mutagenesis?
Insertional
mutagenesis
a DNA payload size depends on the presence of accessory proteins.
b It is still unclear whether recombinant AAVs are capable of stable
integration.
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restoration of the dystroglycan complex at the sarcolemma,
and amelioration of the physiological and pathological indices
of muscle disease [77–79]. Higher doses of vector were needed
to treat adult mdx mice likely due to inefficient infection of
mature muscle by Ad [77].
Even with improvements in Ad vectorology, problems
remain. The episomal Ad genomes are gradually lost from the
transduced myofibers. High-titer neutralizing antibodies arise
against Ad after the first administration of vector, preventing
repetitive administration of Ad vector of the same serotype [80].
The administration of high doses of either first-generation or
hdAd results in the induction of innate and cellular immune
responses, that at very high doses are associated with direct
toxicity that can be lethal [81,82]. Further, systemic delivery of
adenoviral vectors in mice leads to a significant drop in blood
pressure likely due to the systemic activation of endothelial cells
and increased production of nitric oxide, followed by destruc-
tion of Kupffer cells [83]. This acute toxicity is not prevented or
reduced with hdAd. In the case of hdAd the capsid composition
and structure are the same as in the first generation vectors and
would not be expected to reduce the acute innate inflammatory
response against the vector [84,85]. Several investigators are
implementing methods to reduce the associated inflammation
and toxicity. For example, coating the virus with polyethylene
glycol can serve to mask Ad epitopes from preexisting immune
responses by reducing protein–protein interactions [86]. The
use of hdAd can limit the adaptive immune response against Ad
proteins [81], but generation of immunity to the transgene
dystrophin is somewhat controversial in the context of human
gene therapy. Many DMD patients have large deletions within
the dystrophin gene that prevent expression of epitopes encoded
by deleted exons such that exogenously delivered dystrophin
could be perceived as a neoantigen [87]. In this regard, co-
delivery of immunomodulatory molecules such as CTL4AIg
[88] is being re-examined in the context of hdAd dystrophin
delivery. Investigators have shown prolonged dystrophinexpression in immuno-competent mice with systemic gene
transfer utilizing T-cell costimulatory blockade [89,90].
4. Lentivirus
An additional viral vector being tested for gene transfer to
muscle is the HIV-derived lentiviral vector. This retroviral
vector can be produced at moderate titers, can infect both
dividing and non-dividing cells and be pseudotyped with a
variety of different envelope glycoproteins [91]. In contrast to
results with Ad vectors, these vectors do not induce a cytotoxic
T-cell lymphocyte (CTL) response. To address safety concerns,
genetic engineering has produced a lentiviral vector system that
is self-inactivating (SIN) [92]. These vectors have a large
deletion in the 3′ U3 region that contains the viral promoter and
enhancer. This deletion is copied over to the 5′ region during
reverse transcription which in turn abolishes LTR-driven
transcription in transduced cells [91]. Furthermore, lentiviral
vector systems can carry between 7.5 to 9 kb of cargo DNA,
which is largely sufficient for cloning sizeable transgenes such
as minidystrophin, selectable markers, and the promoters
needed for expression. This feature is important, especially
when using large tissue-specific promoters. Finally, lentiviral
vectors have been shown to permanently transduce and stably
express transgenes in muscle cells and their precursors, making
them the delivery system of choice for muscle progenitor cell
based gene transfer [93–95]. In adult skeletal muscle, satellite
cells are the primary stem cells that are responsible for postnatal
muscle growth, hypertrophy, and regeneration. These cells are
normally quiescent but can activate to a proliferative state by
extrinsic signaling mechanisms. Activation of the satellite cell
population is dramatically enhanced in response to muscle
damage or degenerative disease where myoblast generation is
necessary for repair and growth. Upon activation, there is a
proliferative phase where progeny proceed down the myogenic
lineage pathway to become fusion competent myoblasts
[96,97]. However, the transduction of satellite cells using
lentiviral vectors would provide an attractive therapeutic option,
particularly when robust isolation methodologies in the absence
of activation and homing mechanisms become further identi-
fied. A large advantage of this therapy is the potential use of the
patient's own cells and the inherent avoidance of the immune
response. As with many ex vivo approaches there are challenges
and this includes efficient isolation of satellite cells, develop-
ment of optimal expansion conditions, enhancement of efficient
muscle homing mechanisms, and minimization of insertional
oncogenesis within active genes. Numerous other stem cells are
also being studied for potential use in ex vivo gene therapy
strategies for DMD, including mesangioblasts, SP cells and
MAPC [3,98,99].
5. Adeno-associated virus
Among the viral vector systems being utilized today, one that
has generated much optimism towards eventual treatment of
muscular dystrophy is adeno-associated virus (AAV). AAV is
classified as a Parvoviridae family member being of the genus
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identified from primates thus far, and more than one hundred
sequences representing novel clades of AAV have been reported
[100–103]. AAV is a single stranded DNA virus (∼4.7 kb)
whose genome is flanked by inverted terminal repeats (ITRs)
that are ∼150 nucleotides in length. The ITRs are critical for
stability and priming of genome replication through a “rolling
hair pin” mechanism [104]. These elements contain all the cis-
active elements necessary for replication and encapsidation of
AAV genomes [105]. The recombinant-AAVs (rAAV) in use
today are deleted of all viral genes, specifically the rep and cap
genes that encode the nonstructural and structural proteins
respectively. Viral packaging constraints limit the size of the
transgene that may be included to the size of the wild type
genome. rAAV for gene transfer has been developed using a
pseudotyping approach that consists of a recombinant genome
framed by the ITR of AAV serotype 2 and a capsid based on any
one of the cloned AAV serotypes [106]. Recombinant vectors
based on these variants demonstrate significantly different
tropism for tissues such as cardiac muscle, skeletal muscle,
liver, and lung as well as transduction differences in vitro versus
in vivo [107–109].
For the expression of protein using rAAV there is the
requirement of flanking ITRs, a promoter, transgene, and
polyadenylation signal. The production of virions has vastly
improved over the years. Refinement has allowed the use of a
two plasmid system, where the Ad functions and Rep/Cap
ORFs are supplied on a single plasmid [110,111]. The virions
may be purified and concentrated from the cellular lysate by
density gradient centrifugation, ion exchange or affinity chroma-
tography [112–114]. In the case of large-scale production,
column chromatography has a distinct advantage in terms of
logistics. However, one must be aware that this procedure will not
distinguish between virions that contain viral genomes from those
that do not (empty capsids) as density gradient centrifugation
allows. Several serotypes, for example, AAV2 and AAV6 have
the capacity to bind heparin with a relatively high affinity thus
allowing purification by heparin chromatography [112].
Many researchers have focused on the ability to systemically
deliver rAAV carrying truncated versions of dystrophin to
achieve body-wide transduction of the musculature. Though
this is no small accomplishment, we must further address safety
concerns of not only the viral vector, but also the transgene with
more rigorous testing prior to proceeding to clinical trials.
Irrespective to the transgene, the use of rAAV vectors is likely
several years away from being a practical clinical therapy for
DMD. However, there are several characteristics suggesting it
as an attractive candidate for gene-replacement/corrective
therapy. These include the nonpathogenic nature of AAV, the
availability of alternative serotypes with muscle tropism, the
ability to generate vectors at relatively high titer, a relatively low
but not absent immunogenicity, and an ability to achieve long-
term transgene expression. Further improvements in vector
design with the goal of strictly limiting gene expression to
muscle will undoubtedly add to the safety of AAV vectors on
several levels. Optimization of methods to produce enough
rAAV vector for routine use in patients, and the ability todevelop techniques that allow transduction of enough of the
musculature to provide a therapeutic benefit while minimizing
toxicity will favorably influence the realization of therapeutic
success in the clinic. In the future, with combined improve-
ments in production and delivery approaches, these vectors
likely will become more internally customized to a particular
disease. Many of these promising technologies are new and
likely to advance rapidly in the coming years. Analysis of
specific and non-specific toxic effects will have to be a
prominent aspect of future trials, and these will undoubtedly be
balanced against the benefit of this type of treatment.
6. Gene targeting
Gene targeting is the replacement of an endogenous DNA
segment with a homologous, exogenous segment of DNA by
homologous recombination (HR). Homologous recombination
technology has rapidly advanced the field of molecular genetics,
but initially fell short of realization in terms of a gene repair
strategy. This was primarily because vectors used for HR
typically inserted into the host genome at random locations with
a frequency greater than that of HR [115]. However, recently
this area of research has been revitalized thanks to the efforts of
several laboratories offering hope toward efficient chromoso-
mal manipulation. A major advantage of the HR gene targeting
approach is that the risk of random integration as is presented
with retroviral mediated gene replacement [116] can be avoided
or minimized. In one study HR was accomplished by using
hdAd as a vector platform [117]. The frequency of HR using
this system with an 18.6 kb region of homology reached
∼2×1013, while detection of random integration events was
found to be ∼5% per transduced mouse embryonic stem cell at
a multiplicity of infection (moi) of 10. This is a vast
improvement from the 10−5 to 10−7 per infected cell that was
previously demonstrated using E1-deleted replication incompe-
tent Ad to target the single-copy Fgr locus in mammalian cells
[118]. It was also shown that HR could be accomplished on a
relatively small number of cells, which would be of benefit in
the stem cell field. Similarly, a recombinant adeno-associated
virus (rAAV) vector has been used to correct dominant
mutations in mesenchymal stem cells (MSCs) from patients
with osteogenesis imperfecta [119], demonstrating that gene
targeting by HR is possible for non-embryonic stem cells. In
this study 6×105 to 2.3×104 MSCs underwent gene targeting.
This strategy has an advantage of minimizing the possibility of
insertional mutagenesis, and there is the further advantage that
MSCs are typically non-immunogenic.
Recently, an exciting technical development has emerged
with the use of chimeric zinc finger nucleases (ZFNs) where a
FokI endonuclease domain is combined with a zinc finger
protein. When designed properly, this system can exhibit
exquisite sequence specificity and targeted DNA cleavage
[120]. This study demonstrated a remarkable 18% level of gene-
modified human cells without selection. DNA cleavage is
followed mechanistically by stimulation of HR between the
chromosome and the extrachromosomal DNA donor. By
altering the specificity of the zinc finger domain one can alter
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attractive methodology. The ability to engineer ZFNs to target
essentially any sequence clearly establishes the utility of ZFN-
driven genome editing. The same concerns of present-day gene
therapy strategies exist, namely delivery method, associated
toxicity, and a host immune response.
7. Muscle gene transfer
rAAV vectors support stable, long-term gene expression
following infection of muscle cells, where they persist as an
episome [121]. Serotypes that have demonstrated a particular
tropism for the musculature include AAV1, 5, 6, and 8
[108,122–125]. These serotypes have demonstrated a transduc-
tion efficiency of up to 500 times greater than that of AAV2
[103,126–128]. Although wild type AAV is capable of
integration into the host genome in the presence of Rep,
integration of a rAAV genome into myonuclei has not been
detected [129]. Long-term transgene expression of rAAV has
been observed for over 5 years in dogs and rhesus macaques,
and for 2 years in mice [130–134]. Vectors pseudotyped with
capsids from AAV1, 6, and 8 display peak expression several
weeks prior to that of AAV2 [126,135,136]. This delay in
transduction is quite significant for a disease such as DMD
where there is a rapid turnover of muscle fibers [137].Fig. 3. Whole-body human placental alkaline phosphatase (hPLAP) gene transfer to
into the tail vein of a 3-month-old wild-type mouse, and tissues were analyzed 20 m
Ringer's solution containing 0.008% mouse serum albumin and 2 IU sodium hepari
hPLAP as detected by NBT/BCIP (30 min following 90 min heat inactivation at 65 °C
the heart, quadricep, and tibialis anterior muscles. Top row, muscles from wild-type m
injected with Ringers buffer solution.The route of administration of rAAV is a major consideration
for the treatment of DMD, taking into account that body wide
distribution would likely be necessary for an effective therapy.
Previous efforts to target organs such as the diaphragm or heart,
whose failure accounts for the majority of patient deaths, have
utilized invasive surgical procedures for intravenous (IV) vector
delivery using potentially toxic cofactors to induce vascular
permeability [138]. Although such studies yielded beneficial
results, they underscore the need to deliver a therapeutic vector
in a noninvasive manner. In another approach, researchers
administered viral vector to rodents intra-arterially using high
pressure injections [139]. More recently, the ability to transduce
the entire cardiac and skeletal musculature of a mouse has been
accomplished with a single low pressure intravenous adminis-
tration of rAAV6 [140]. The inclusion of vascular endothelial
growth factor (VEGF) was shown to dramatically increase the
efficiency of this method at lower vector doses [140]. This
response to VEGF was not observed at higher vector doses
(>1012 vg). Importantly, IV administration of rAAV6 demon-
strated efficient transduction of the diaphragm and intercostal
muscles that are vital to respiration [140]. In a follow up study
in which rAAV6 encoding human alkaline phosphatase was
delivered by IV administration, persistence of transgene
expression was demonstrated out to 20 months in mice
(Fig. 3). Since this initial demonstration there have beenthe musculature using rAAV6. 1×1012 vg of rAAV6/RSV-hPLAP was injected
onths later. Vector was administered in a 300-μl bolus injection in physiological
n. VEGF was not used in this study. All striated muscles were found to express
) in essentially every myofiber or myocyte. Shown are representative sections of
ice injected with rAAV/RSV-hPLAP; bottom row, muscles from wild-type mice
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a similar vein [125,141–148]. Additional optimization is
warranted in order to allow for a lower effective dose in larger
animal models, providing for a decreased potential for toxicity
and a safer outcome. The low immune response elicited by rAAV
vectors in animal studies suggests that this vector may have a
distinct advantage over others such as Ad [134,149]. To date
there is little evidence for rAAV vectors causing direct toxicity in
either animal studies or human clinical trials. Doses up to
1012 vg/kg of rAAV have been well tolerated in human studies
with no toxicity [134,150,151]. However, evaluation of clinical
samples from a recent hemophilia trial revealed a cytotoxic T-
cell (CTL) mediated immune response that was likely generated
by memory CD8+ T cells against the AAV capsid. This immune
response resulted in a decline of transgene (Factor IX)
expression and hepatic injury supported by an elevation of
alanine and aspartate transaminases [152]. While these data are
from a relatively small sample size, it should be considered
carefully when proceeding to human clinical trials given the
frailty of older DMD patients.
8. Gene repair strategies
It has recently been reported by the International Human
Genome Sequencing Consortium (IHGSC) that the human
genome contains ∼25,000 gene loci covering ∼1.7 Gb, with
231,667 protein-encoding exons. The tremendous size of the
DMD gene represents an enormous target for genetic mutations.
Approximately 20% of the mutations leading to DMD are point
mutations or small insertions or deletions that effect one or a
few exons [153]. With that in mind, nature has provided us with
a clue for an alternative gene therapy approach to the gene
replacement strategy. DMD patients occasionally have rare,
dystrophin positive fibers (revertant fibers) that likely originate
from exon skipping in the dystrophin gene and which generate a
truncated transcript with a restored open reading frame [154].
Exon skipping therapy is based on the reading frame rule [155]
which states that frame-shifting mutations in the dystrophin
gene result in DMD, while frame-conserving ones primarily
lead to a milder Becker muscular dystrophy (BMD). Thus, the
ability to induce exon skipping has the potential to convert a
DMD phenotype to a much less severe BMD phenotype.
Several laboratories have demonstrated induction of exon
skipping [12] using synthetic antisense oligonucleotides
(AONs) [9,156,157]. These AONs bind to specific sequences
in the pre-mRNA and thus disturb exon inclusion signals such
as splice sites, intronic branch point sequences, or exonic
splicing enhancer elements. In turn, this leads to removal of the
targeted exon by inhibiting its inclusion within the processed
mRNA.
One model to test the induction of exon skipping is through
the targeted skipping of exon 23 in the mdx mouse. This exon
contains a nonsense mutation that results in dystrophin
synthesis being aborted prematurely. The researchers used an
AON that targets the 5′splice-site of this exon, in combination
with a drug carrier called F127 [156] (a block copolymer
belonging to the group of amphiphillic pluronics used in thepharmaceutical industry). This drug carrier enhances the
circulation time, metabolic stability, and transport of AONs
across the cell membrane. It was demonstrated that AON-
induced skipping of exon 23 could be therapeutic as up to
∼20% of the muscle fibers in the mdx mouse were converted to
a dystrophin positive state with positive functional conse-
quences. The distribution of the dystrophin positive fibers was
highly variable which was attributed to the regeneration process
in individual mdx muscle fibers that led to differential uptake of
the AONs. After repeated administration, dystrophin levels
were shown to be 1–5% of normal. Absence of dystrophin
expression in the heart and the increased dystrophin in older
mdx mice compared to younger mice further indicate a role of
the regenerative process on AON uptake. The lack of expression
in cardiac tissue is a concern considering more than 30% of
DMD-associated deaths occur as a result of cardiomyopathy
[158].
In a more efficient and persistent strategy, rAAV was used to
deliver AONs as part of either U1[157] or U7 small nuclear
RNAs [9]. The latter study utilized a previously described
antisense-plasmid system (U7mOPT) [159] that contains a
modified U7snRNA gene (U7mOPT). This RNA, as a part of
the U7 ribonucleoprotein particle, is involved in the processing
of the 3′ end of histone pre-mRNAs within the nucleus through
an antisense mechanism. Within the U7mOPT, the original U7
antisense sequence was replaced with two antisense sequences.
These sequences target the branch point sequence in intron 22
and the 5′ splice site of exon 23. After intramuscular injection of
the rAAV-U7-AON vector in mdxmice up to 77% of dystrophin
positive fibers were observed, and 3 months following
administration a 50% level was reported. Taking this approach
one step further by using the systemic delivery capability of
rAAV, it was demonstrated that AAV-mediated antisense-U1
small nuclear RNA expression resulted in effective dystrophin
production through the hind limb of an mdx mouse, significant
recovery of the functional properties in vivo, and lower serum
creatine kinase levels, suggesting an overall decrease in muscle
wasting [157].
In order to test the effectiveness of the AON strategy in the
context of human dystrophin a hDMD transgenic mouse was
developed with the full-length human DMD gene [160]. This
model demonstrated that the targeting of human exons with
AONs can induce their specific removal from the human DMD
transcript. Further, showing exquisite specificity, no detectable
effects in the homologous mouse dystrophin transcript were
detected.
9. Immune evasion strategies
Any viral-mediated gene delivery method can potentially
lead to a destructive host immune response against vector
proteins. This result can occur by cell transduction and antigen
presentation in the context of the major histocompatibility
complex, resulting in elicitation of a CTL response that destroys
transduced cells. It must also be considered that DMD patients,
whose muscles do not express dystrophin, may be more likely
to develop an immune response to vector-delivered dystrophin
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of dystrophin. Therefore, patients with different mutations may
respond differently to gene transfer. Understanding the
mechanisms by which vector-encoded proteins are recognized
by the immune system in order to develop approaches to
prevent induction of an immune response is of utmost
importance. Various immunosuppressive protocols have been
shown to potentially circumvent this dilemma. For example,
transient depletion of CD4+ Tcells during the initial exposure to
rAAV allowed successful readministration of AAV vectors to
skeletal muscle [161]. Similarly, the use of anti-CD40L
antibodies, which block T cell activation of B cells, allowed
prolonged gene expression in mouse lung [162]. These
treatments would be expected to inhibit the initiation and
expansion of a primary immune response and promote viral
delivery of a transgene [161,163]. However, these approaches
would be less effective in humans that possess an arsenal of pre-
existing neutralizing antibodies that could block readministra-
tion of the viral vector.
Recently a large (>106) AAV-2 capsid library was generated
with randomly dispersed capsid mutations in a process similar
to DNA shuffling [164]. This approach was applied to a
clinically relevant problem of AAV: preexisting immunity in the
human population. In this case the authors applied repeated
amplification of those AAV2 mutants that retained infectivity in
the presence of antisera with increasing titer of neutralizing
antibody [164]. The results were impressive: numerous anti-
body-evading mutants were obtained, one which showed the
ability to moderately transduce cells while in the presence of a
1:2 antiserum dilution. When neutralizing antibodies to other
AAV serotypes as well as crystal structures become available an
AAV capsid regional immunogenic profile should become
possible. These data have the potential to bring a wealth of
knowledge to our current understanding of antigenicity of the
AAV capsid and when combined with the knowledge of the
altered tropism capacity of AAV serotypes [165] provides a
powerful tool for therapeutic applications.
The promoter is an important consideration in determining
both the level of expression and tissue specificity of rAAV-
mediated gene transfer. Tissue specific gene expression within
skeletal muscle has been achieved using the synthetic C5-12
promoter [166], the muscle creatine kinase (MCK) promoter
[167] and the desmin promoter [168]. However, even when
tissue-specific promoters are employed clearance of the vector
from the bloodstream can occur from high levels of neutralizing
antibody to the viral capsid or transgene product. It would be of
great interest to specifically tailor transgene cassettes so that the
gene expression could be prevented in undesirable cell types
such as immune effector cells. Restricting expression with the
use of tissue-specific promoters may also limit the potential
efficacy of gene transfer by constricting the population of cells
expressing the transgene.
Recently, micro RNA (miRNA) regulation was demon-
strated within a lentiviral system to prevent transgene expres-
sion in hematopoietic lineages while permitting high expression
in nonhematopoietic cells [169]. miRNAs are a family of small
(∼21mer) RNAs that, at least for those that have characterizedtargets, negatively-regulate gene expression at the post-
transcriptional level [170–173]. The researchers incorporated
four tandemly positioned copies of a 23-bp sequence (mirT)
within the 3′ untranslated region of green fluorescent protein.
This design provides complementary target sequence to multi-
ple miRNAs with the intention of optimizing repression of the
transgene. The selection of targets was based upon emerging
constraints of miRNA mediated regulation [174,175]. This
system was found to be an improved means for preventing
expression in hematopoietic lineage cells when compared to a
hepatocyte-specific albumin promoter which may have also
better prevented cross-priming of the T-cell population to
professional APCs. This improved ability to exclude expression
was suggested to occur because post-transcriptional regulation
can trump off-target promoter activity. The engineering of
miRNA-mediated regulation into a viral vector could poten-
tially allow for an exquisite layer of control over transgene
expression at the level of transcription irregardless of the
relative strength of the promoter, and as such potentially
allowing avoidance of the host immune response.
10. Addressing the rAAV carrying capacity limitation
One of the most challenging aspects of developing rAAV for
the treatment of DMD is the limited DNA packaging capacity of
the capsid. The upper limit capacity of rAAV for foreign DNA is
considered to be ∼5 kb [176] while the coding region of
dystrophin covers 11.2 kb of cDNA sequence. Three
approaches have explored the ability to circumvent this size
constraint, namely the minigene, trans-splicing, and recombina-
tion vector approaches. Patients with mild phenotypes of
muscular dystrophy have been described that arise from large
deletions within the dystrophin gene [74]. It was concluded that
large portions of the gene are not vital for function (Fig. 1).
Several transgenic mdx mice were engineered to carry different
deletions throughout the four dystrophin domains in order to
map the regions that are crucial for function. Mild phenotypes
were associated with N-terminal domain deletions, indicating
that this region is important but not essential for attachment to
actin and the cytoskeleton [177]. The evaluation of a series of
large deletions within the central rod domain indicated that as an
entirety this structure is indispensable but the number of
spectrin repeats can be markedly reduced [13,137,178]. Also
the proper positioning of the repeats and the presence and
configuration of the hinge regions is crucial. Deletions in the
cysteine-rich domain cause severe dystrophy, also resulting in
disrupted expression of the entire DGC [179]. The C-terminal
domain was found not to be required for assembly of the full
DGC [179,180]. Engineered to mimic and improve upon the
exons 17–48 deletion in a BMD patient [74], the 6.2 kb
minidystrophin construct (ΔH2-R19) contains 8 repeats and
hinge regions 1, 3 and 4. This construct was found to be
completely functional, in that mdx mice that expressed this
mini-dystrophin demonstrated normal muscle morphology and
force generation. Several microdystrophin constructs (3.6–
4.2 kb) have also been developed that display a highly effective
ability to support near normal muscle structure and function in
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spectrin-like repeats have been delivered to mouse muscle
by rAAV. These constructs have been shown to ameliorate
many of the dystrophic pathophysiological effects in the mdx
mouse such as increased susceptibility to eccentric contrac-
tion-induced injury, high proportions of centrally-nucleated
myofibers, and elevated levels of serum creatine kinase
[13,137,140,167,182,183]. The micro-dystrophin found to
have optimal characteristics of effectiveness and small size
was the construct ΔR4-R23/ΔCT, which spans 3.6 kb of DNA
and carried 4 spectrin-like repeats and hinges 1, 2 and 4 while
lacking the C-terminal domain. Although most microdystro-
phins vastly improve the phenotype of mdx mice, restoration of
the muscles to complete parity with those of wild type mice is
not accomplished. There is not a full restoration of absolute or
specific force generation, and the degree of correction is both
age and muscle dependent [167,182]. Importantly, in young and
old mdx mice, microdystrophin mediated correction of the
abnormal properties of the diaphragm is significantly more
effective than in limb muscles. This observation is noteworthy
considering the phenotype in the diaphragm of the mdx mouse
much more closely mimics the pathology found in human
muscle and many patients succumb to respiratory failure. Even
with these encouraging results it is possible that other more
effective microdystrophins could be engineered.
Two such strategies have come to light that may allow larger
minidystrophins to be expressed by rAAV delivery. The first is
gene expression following trans-splicing. This approach utilizes
two rAAV vectors with the transgene split between them. The 5′
gene portion is followed by a splice donor sequence from a
natural dystrophin intron without a polyadenylation signal
while the 3′ gene portion is preceded by a splice acceptor from
the same intron, followed by a polyadenylation signal [182].
Expression of the large protein occurs in co-infected cells,
where the viral genomes concatamerize, and cell mediated
splicing generates an mRNA for a minidystrophin. RNA
processing thus represents a crucial barrier to the efficiency of
cellular transduction using this vector system. The sequence
environment of these splice sites and their location within the
split gene can have profound influences on transcription and
splicing efficiencies [184,185].
Another system that utilizes a dual vector strategy is often
referred to as recombination or overlapping rAAV vectors. In
essence, two rAAV vectors containing overlapping fragments of
a larger gene are delivered simultaneously to cells resulting in
homologous recombination at the overlap such that the larger
gene is reconstituted [186–188]. The efficiency with which
transduction occurs using the recombination system can be
influenced by the AAV serotype, desired tissue target, and the
specific transgene overlap composition. In mouse lung it was
demonstrated that rAAV6-Alkaline phosphatase (AP) was
superior to that of rAAV2-AP, where the degree and distribution
of transduction of the former recombinant vectors was similar to
the parental intact vector. Similarly, rAAV6 recombination
vectors have been found to be more efficient in skeletal muscle
than rAAV2 counterparts [186]. Further, this study demonstrated
that the transgene overlap can influence the recombinationkinetics. This observation implies that sequence characteristics
of the overlap region such as degree of secondary structure, and
GC content should be taken into account when designing such a
system.
11. Compensatory therapeutics
11.1. Utrophin
The spectrin superfamily of proteins includes dystrophin,
utrophin (formerly called dystrophin-related protein, or DRP),
DRP2, and dystrobrevin [189–191]. There is a high degree of
sequence similarity between dystrophin and utrophin at both the
DNA and protein levels [191,192]. Similar to dystrophin,
utrophin is encoded by many small exons over a relatively large
genomic region (∼1 Mb) [193]. Additionally, transcription is
carried out from several promoters [131], and several truncated
isoforms have been identified [138,194,195]. In normal skeletal
muscle utrophin is found concentrated at the myotendinous and
neuromuscular junctions, whereas it is localized under the entire
sarcolemma in regenerating fibers present in mdx skeletal
muscle [196,197]. In skeletal muscle, utrophin is detectable in
early fetal development over the sarcolemma where during
development it is gradually replaced by dystrophin [198]. This
difference in developmental expression has resulted in the
proposal that utrophin may be the embryonic/neonatal form of
dystrophin [199], implying that utrophin provides dystrophin-
like function in embryonic and developing skeletal muscle.
Recent evidence has come to light that may partially begin to
explain some of these modest differences in terms of the
structural/functional relationships of these two quite similar
proteins. Alternative molecular mechanisms of beta-dystrogly-
can [200] and actin filament interactions [201–203] for utrophin
when compared to dystrophin have been put forth. It may be that
subtle differences or undisclosed areas within or adjacent to the
N-terminal or cysteine-rich domains may impart a more
significant contribution to binding affinity than previously
considered. This would be of obvious importance when
considering the development of micro or mini genes for thera-
peutic potential. In contrast to dystrophin, whose actin binding
domain resides within the amino terminus and the central rod
domain (Fig. 1); utrophin actin binding capacity resides in the
continuous segment that includes the amino terminus and the
first ten spectrin-like repeats of the rod domain [202]. Given this
arrangement, and the degree of developmental expression,
utrophin has been proposed to act as a stabilizer of newly formed
actin filaments during costamere development [203]. Addition-
ally, given the non-competitive nature of dystrophin/utrophin
binding the overlapping expression of these two proteins may
provide for an effective changing of the muscle fiber guard
during the period shortly after birth of utrophin downregulation
and dystrophin upregulation.
This expression pattern led to the hypothesis that utrophin
may be able to functionally compensate for dystrophin in DMD
patients [204]. This idea was supported by studies in mdx mice
where it was found that elevation of utrophin levels in
dystrophic muscle fibers restored sarcolemmal expression of
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concept of upregulating utrophin to allow for a replacement of
dysfunctional or absent dystrophin provides promising ther-
apeutic possibilities for DMD. For example, adenovirus
delivery of utrophin in muscle has shown phenotypic improve-
ment in mdx and double knock-out (dko) mice that are deficient
for both utrophin and dystrophin [205,206]. In the dko mice
administered the utrophin minigene neonatally, expression was
detected 30 days post-injection in ∼95% of myofibers within
the limb muscle, providing protection from subsequent
dystrophic damage in dystrophin deficient muscle. Further,
transgenic mdx mice that expressed full-length utrophin mRNA
had a more improved outcome in preventing dystrophy even with
relatively low levels of expression [207]. Thus, experimental
evidence suggests that a gene transfer approach focusing on the
exogenous delivery of utrophin to DMDmuscle fibers is a viable
treatment option for this disease. As well, there is an added
benefit to this approach; the lack of neoantigen production and
subsequent immune response against the transgene that might
result with the delivery of dystrophin [208].
Further evidence that utrophin can functionally compensate
for the lack of dystrophin in muscle was provided by a
transgenic mdx mouse line that expressed a mini-utrophin in
muscle [209]. The results were striking: histochemical analysis
demonstrated a dramatic decrease in fibrosis, necrosis, serum
creatine kinase levels, and the frequency of centrally nucleated
myotubes. It is noteworthy that no toxicity was associated with
high-level expression of utrophin, even in non-muscle tissues
[201,207,210]. Subtle structural differences between dystro-
phin and utrophin are known. For example, there is a short
extension in the N-terminal domain that is absent from
dystrophin that results in a greater binding affinity for actin.
Also these two proteins do not appear to compete for binding
sites on actin [203,211,212]. Furthermore, a difference can be
found when comparing the rod domain of these two proteins
though it is thought that this region has been under less
selective pressure [74]. Obvious differences include a less
defined first hinge following the N-terminal domain, two fewer
spectrin-like repeats, and the lack of basically charged spectrin-
like repeats that provide a second actin-binding domain in
dystrophin [213]. These differences are in contrast to the
cysteine-rich and C-terminal domains, which display ∼80%
amino acid sequence identity between dystrophin and utrophin
[214].
12. Endogenous utrophin up-regulation
A number of labs have investigated the possibility of
stimulating endogenous utrophin expression by pharmacologi-
cal intervention. A challenge with this approach is achieving
increased expression of utrophin along the entire length of
myofibers to act as a dystrophin surrogate. In order to
accomplish this one must begin to understand what motifs
within the DNA are responsible for restricting utrophin
expression at the neuromuscular junction and for allowing
more widespread expression in developing and regenerating
myofibers. Several labs are using such analyses to developsmall-targeted molecules that might enable upregulation of the
gene in all myonuclei. A more thorough understanding of trans-
acting factors and their appropriate signaling pathways would
be of great benefit towards the design and delivery of specific
molecules to induce targeted transcriptional activation.
Recently, the delivery of a small peptide region of the heregulin
ectodomain to mdx mice increased utrophin expression and
ameliorated the dystrophic phenotype [215]. The improvements
appeared to be a result of utrophin up-regulation as the same
treatment in the dko model failed to improve muscle pathology.
However, the benefits obtained were not as dramatic (∼2–3
fold) as those obtained previously by somatic gene transfer of
mini-utrophin genes [205].
In addition to transcriptional regulatory mechanisms,
utrophin appears to be regulated post-transcriptionally [216–
219]. Regions within the 3′ untranslated region have been found
to be responsible for targeting and stabilizing utrophin
transcripts, allowing a potential means of sustaining increased
levels in muscle. Studies in vivo have demonstrated that post-
transcriptional processing plays a contributory role towards
increased utrophin transcript stability in slow versus fast twitch
muscle [219]. It has been proposed that this may be regulated by
calcineurin levels [220]. This study indicated that transgenic
mice overexpressing calcineurin showed increased utrophin
mRNA levels, thought to be mediated through NFAT signaling,
an effector of calcineurin. Inhibition of calcineurin resulted in
an ∼80% decrease in utrophin mRNA levels. An internal
ribosomal entry site (IRES) has also been identified within the
5′ untranslated region of utrophin. This IRES has been shown to
regulate the expression of utrophin during muscle regeneration
[221]. Further, post-translational mechanisms have been
implicated in utrophin expression such as the involvement of
calpain-mediated proteolysis [222], and the GTPase RhoA was
found to stabilize and aid in localization of utrophin protein in
muscle cell cultures [223]. All together, each of these regulatory
events represent potential targets for the development of
strategies designed to increase endogenous utrophin in
dystrophin deficient myofibers.
13. Muscle supportive therapy
In the absence of utrophin-based therapy, successful
treatment of DMD will likely require gene replacement or
correction of the genetic defect. However, given the complexity
of the symptoms associated with this progressive disease it is to
be expected that therapies may need to be tailored to a particular
stage of the disease process. In addition to dystrophin family
members, a variety of genes or compounds have been put forth
as therapeutic candidates in an effort to address the varied arms
of DMD pathogenesis. Most of these approaches are aimed at
promoting cellular adhesion, reducing inflammation and
eventual necrosis, and sustaining the regenerative capacity; all
of which appear to aid in muscle stability. We will present a
highlight of potential candidates that can be delivered to muscle
using viral vectors many of which may even provide a
synergistic effect in combination with dystrophin/utrophin
delivery.
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Within muscle there are two major cell adhesion complexes
that provide muscle fiber attachment to laminin in the basal
lamina, the DGC and α7β1 integrin. In transgenic mdx:utrn−/−
dko mice modest (2–3 fold) overexpression of integrin α7 was
sufficient to significantly extend lifespan [224]. Further, the
heterodimeric partner β1D was also restored, and the transgenic
mice displayed reduced kyphosis and muscle disease pathology.
Additionally, delivering α7 integrin with rAAV to muscle, as
with utrophin, would have the advantage of not producing an
exogenous protein that could be recognized as foreign by the
immune system. An additional protein found to be involved in
cellular adhesion is a component of the DGC, namely α-
dystroglycan (α-Dgn). α-Dgn binds to several extracellular
ligands, including laminin, agrin and perlecan in muscle (Fig. 2)
[225–228]. Recent reports have shown that this interaction is
strictly dependent on the glycosylation status of α-dystroglycan
[229–231]. In one study a dramatic beneficial effect on
degeneration and histopathology was observed in mdx mice
that overexpressed N-acetyl galactosamine [232]. This result
was suggested to strengthen the link to laminin in the
extracellular matrix. Along that same line, overexpression of
the glycoslytransferase LARGE was demonstrated to function-
ally bypass α-dystroglycan glycosylation abnormalities in a
model of congenital muscular dystrophy [233]. It is possible
that additional forms of post-translational modifications may
serve as potential therapeutic targets to support muscle in
multiple forms of muscular dystrophy.
15. Intracellular signaling and inflammation
ERKs act as an integrative point for multiple biochemical
signals, and are involved in a wide variety of cellular processes.
One such process is mechanical stress of muscle fibers where a
strong correlation between peak tension and ERK phosphoryla-
tion in situ suggests these MAP kinases are particularly
responsive to muscle damage [234]. Considering that myofibers
in vivo are continually subjected to mechanical forces,
disregulation of this pathway and others in response to
mechanical stress could impart a considerable role on the
progression of muscle pathogenesis. Another MAP kinase, JNK
is also activated in mdx mice, and be involved in pathogenesis
[235]. Nitric oxide, the product of nitric oxide synthase,
functions as the major endothelial-derived relaxing factor.
Skeletal-muscle-derived NO functions as an important vasodi-
lator [236]. The activity and expression of nNOS are regulated
by both myogenic and neurogenic factors while the association
of nNOS with the sarcolemma is mediated by the DGC (Fig. 2).
More specifically, nNOS is linked to the DGC through alpha-1-
syntrophin PDZ–PDZ domain interactions where production is
stimulated by muscle contraction. By a yet to be resolved
mechanism, NO opposes alpha-adrenergic vasoconstriction. As
a by-product of NO, increased production of cGMP may
contribute to the inhibition of receptor-mediated Ca++ influx in
vascular smooth muscle. In the case of DMD and the absence of
dystrophin, nNOS is not properly localized to the sarcolemma[33]. In this circumstance nNOS protein is inappropriately
localized within the cytosol, and the absence of nNOS from the
sarcolemma can impede NO-mediated regulation of vasodila-
tion [237,238]. DMD muscle was shown to have abnormal
vasoconstriction during mild exercise, resulting in muscle
ischemia induced by inadequate blood flow to actively
contracting muscle [236].
The sarcoglycan (SG) complex is an integral subcomplex of
the DGC, and in muscle consists of α, β, γ, and δ-SG (Fig. 2) all
of which are glycosylated [49]. Evidence that the /δ-sarcoglycan
core can associate with the C-terminus of dystrophin indepen-
dent of dystroglycan or syntrophin was recently demonstrated
[239]. It was further suggested that the interaction between the
sarcoglycans and dystrophin is dependent upon the conforma-
tion of the sarcoglycan complex. This conformational change
may also have an affect on membrane targeting or localization
as well as post-translational modification events. The intracel-
lular regions of α, β, and γ-SG have tyrosine phosphorylation
sites and it has been shown in cell culture that adhesion leads to
phosphorylation of each of these SGs [240]. In vitro, these SGs
are phosphorylated by Src kinase [240], similar to the
phosphorylation of focal adhesion proteins by integrin-activated
kinases (FAK and Src). Recently it has been shown that the SG
subcomplex plays a role in mechanical signal transduction in
skeletal muscle, where changes in the phosphorylation status of
ERK was demonstrated in muscles from γ-SG null (gsg−/−)
mice when compared to mdx muscles [31]. It would be
interesting to determine if aberrant ERK phosphorylation that
arises in these mice is associated with impaired nNOS signaling.
Because the SG subcomplex has been suggested to interact with
α-dystrobrevin [45], it may be that the absence of the SGs
affects the manner in which nNOS is activated.
The use of antibodies to block the action of tumor necrosis
factor alpha (TNF-α), a proinflammatory cytokine also involved
in signaling, resulted in reduction in the breakdown of dys-
trophic muscle in mdx mice [241]. This result may be tied to
NFκB activation [242,243] which appears to play an important
role in muscle wasting [244]. The use of rAAV to deliver the
TNF-α soluble receptor in conjunction with microdystrophin
may be of benefit in more advanced cases of DMD.
The sarcolemma is also susceptible to microrupture in
dystrophic muscles [245] which leads to increased levels of
intracellular Ca2+ and by extension altered Ca2+ signaling, and
calpain-mediated proteolysis resulting in muscle degeneration
[246]. This idea is consistent with the original formulation of
the calcium hypothesis of muscular dystrophy [247]. Interest-
ingly, a recent subproteonomics analysis revealed that a major
luminal Ca2+ binding protein, calsequestrin and the previously
implicated Ca2+ shuttle element, sarcalumenin [248] are greatly
reduced in mdx skeletal muscles [249]. By extension, Ca2+
exchangers, Ca2+ pumps, and Ca2+-binding proteins may
represent viable therapeutic targets for preventing muscle
fiber degeneration. Alteration of Ca2+ cycling may prove useful
in avoiding Ca2+-related proteolytic processes, and future
studies may address whether this can be combined with other
muscle supportive therapies in order to improve long-term
muscle mass and strength.
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process, for example disregulation of signaling pathways,
provides additional targets that may modify the disease process.
Admittedly, the normal localization of signaling proteins to the
sarcolemma likely will not be restored in the absence of an
intact DGC, but promotion of muscle cell integrity and survival
may be accomplished by exogenous regulation of their
downstream effectors. It may be that a combination of agents
to simultaneously provide mechanical muscle support, and to
fortuitously regulate perturbed pathways could have a more
significant benefit.
16. Myostatin and IGF-1
Two potential therapies have been considered for increasing
muscle mass. The first is by delivery of insulin-like growth
factor-1 (IGF-1). IGF-1 is a signaling peptide involved in
muscle myogenesis, which works by enhancing myoblast
proliferation, differentiation and survival. Moderate over-
expression of IGF-1 in mdx muscles yielded increased muscle
mass and strength with decreased necrosis and fibrosis
[250,251]. Similarly, delivery of IGF-1 using rAAV has been
shown to result in phenotypic improvement of dystrophic
muscles [251,252]. One study suggested an increase in cellular
survival was promoted in the absence of dystrophin by
showing a dramatic increase in the phosphorylation status of
the anti-apoptotic protein akt in mdx mice that received IGF-1
[253]. Another target candidate is the protein myostatin, a
TGF-β family member which is a negative regulator of both
muscle fiber number and size [254]. Although the precise
mechanism by which myostatin inhibition results in increased
muscle mass has not been fully elucidated, one report has
proposed delayed differentiation coupled with enhanced
activation, renewal, and proliferation of satellite cells as a
likely mechanism [255]. Whatever the mechanism, it likely
does not involve compensation by utrophin [256]. A number
of studies have shown that there is indeed a benefit to
dystrophic muscles from the blockade of myostatin. However,
what the precise benefit is remains debatable. In one study,
mice null for both dystrophin and myostatin were generated.
As expected, there was increased muscle mass, though in
contrast to a study that used neutralizing antibody to myostatin
on young mdx mice [256], a significant reduction in necrosis
and inflammation was not observed [257]. The mdx mouse
may not be the best model considering that muscles in these
mice do not have a robust regenerative capacity. This approach
to therapy holds much promise particularly in combination
with a dystrophin or utrophin replacement approach as there
are several myostatin inhibitors that could be co-delivered
systemically with rAAV, such as follistatin and the myostatin
prodomain [254,258]. This approach would allow for an
increase in the integrity of the sarcolemma membrane via
restoration of the DGC, as well as added muscle mass and
strength that may be necessary to provide a better clinical
outcome. In addition, as we develop a better understanding of
muscle biology and other biological processes such as aging
and atrophy there may be signaling pathways that are revealedwhose mediators can become candidates for additional vector-
based modulation of muscle.
17. Conclusion
Conceptually the replacement of dystrophin by gene transfer
represents an appealing and simplistic approach for the
treatment of DMD. However, even though technological
advances have allowed small successes in a variety of diseases
and animal models, the ability to optimally integrate these
advances into a therapy for a human disease that is as
complicated as DMD likely requires a more complete under-
standing of the disease process. Understanding the underlying
mechanisms of the degenerative process in the dystrophic
muscle fiber is still preliminary and requires consideration of
multiple mechanisms and approaches for analysis. Various
processes that occur in normal and dystrophic muscle develop-
ment should be considered in order to shed more light on how
muscles degenerate. Finally, the effects on the entire muscu-
lature must also be considered because the challenge to retain
functionality long-term in proper balance related to movement
and posture of the patient will undoubtedly surface.
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